Teradyne Reports Third Quarter 2009 Results

October 28, 2009 6:31 PM EDT

-- Diluted non-GAAP earnings of $0.14 per share, up from loss of $0.21 in Q2'09 and up 56% from Q3'08

-- Revenue of $262M, up 55% from Q2'09 and down 12% from Q3'08

-- Q4'09 Revenue guidance of $255 million to $270 million

NORTH READING, Mass.--(BUSINESS WIRE)-- Teradyne, Inc. (NYSE: TER) reported revenue of $262 million for the third quarter of 2009. Semiconductor Test revenue totaled $173 million and Systems Test Group revenue totaled $89 million. On a non-GAAP basis, Teradyne's income from continuing operations in the third quarter was $24.8 million, or $0.14 per diluted share, which excluded restructuring charges, acquired intangible asset amortization and special items. GAAP income from continuing operations for the third quarter was $6.7 million, or $0.04 per diluted share.

Bookings in the third quarter of 2009 were $288 million of which $233 million was in Semiconductor Test and $55 million in Systems Test Group.

Guidance for the fourth quarter of 2009 is for revenue of $255 million to $270 million, with Non-GAAP net income per share of $0.12 to $0.17 and GAAP net income per share between $0.04 and $0.09. Non-GAAP guidance excludes restructuring charges, acquired intangible asset amortization and special items.

"Our Semiconductor and Systems Test businesses continued to gain strength through the quarter driving our return to operating profitability and positive outlook for Q4," said Teradyne President and CEO Mike Bradley. "We reached a major milestone in our expansion into new markets as we received initial orders for the UltraFLEX-M high-speed memory test system."

Webcast

A webcast to discuss third quarter 2009 results, along with management's business outlook will be held at 10 a.m. EDT, Thursday, October 29. Interested investors should access the webcast at www.teradyne.com and click on "Investors" at least five minutes before the call begins. The webcast replay will be available on www.teradyne.com. In addition, a conference call replay will be available approximately two hours after the call. The replay number in the U.S. & Canada is 800-642-1687. The replay number outside the U.S. & Canada is 706-645-9291. The pass code for both numbers is 36016837. The replay will be available via phone and web site through November 13, 2009.

Non-GAAP Results

In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Teradyne reports non-GAAP results in order to better assess and reflect operating performance. Management believes the non-GAAP measures help indicate Teradyne's baseline performance before gains, losses or other charges that may not be indicative of our current core business or future outlook. Teradyne believes these non-GAAP measures will aid investors' overall understanding of its results by providing a higher degree of transparency for certain expenses and providing a level of disclosure that will help investors understand how Teradyne plans and measures its own business. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at www.teradyne.com by clicking on "Investors" and then selecting the "GAAP to Non-GAAP Reconciliation" link. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

About Teradyne

Teradyne (NYSE: TER) is a leading supplier of Automatic Test Equipment used to test complex electronics used in the consumer electronics, automotive, computing, telecommunications, and aerospace and defense industries. In 2008, Teradyne had sales of $1.1 billion. For more information, visit www.teradyne.com. Teradyne(R) is a registered trademark of Teradyne, Inc. in the U.S. and other countries. All product names are trademarks of Teradyne, Inc. (including its subsidiaries) or their respective owners.

Safe Harbor Statement

The forward-looking statements included in this release are made only as of the date of publication. Teradyne disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

This release contains forward-looking statements regarding future business prospects, Teradyne's results of operations and market conditions. Such statements are based on the current assumptions and expectations of Teradyne's management and are neither promises nor guarantees of future performance. You can identify these forward-looking statements based on the context of the statements and by the fact that they use words such as "will," "anticipate," "expect," "project," "intend," "plan," "believe," "target" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. There can be no assurance that management's estimates of Teradyne's future results or other forward looking statements will be achieved. Important factors that could cause actual results to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased product demand; delays in new product introductions; lack of customer acceptance of new products; unanticipated delays in or costs and expenses relating to the implementation of cost reduction plans; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the "Risk Factors" section of Teradyne's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and Quarterly Report on Form 10-Q for the period ended July 5, 2009. The forward-looking statements provided by Teradyne in this press release represent management's views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management's views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne's views as of any date subsequent to the date of this release.


TERADYNE, INC. REPORT FOR THIRD FISCAL QUARTER OF 2009

CONDENSED CONSOLIDATED OPERATING STATEMENTS

(In thousands, except per share amounts)

                        Quarter Ended:                          Nine Months Ended:

                        October 4,   July 5,      September     October 4,    September
                        2009         2009         28, 2008      2009          28, 2008

Net Revenues            $ 262,162    $ 169,580    $ 297,255     $ 552,350     $ 912,275

 Cost of Revenues (1)     155,407      122,451      169,325       365,106       491,994

Gross Profit              106,755      47,129       127,930       187,244       420,281

Operating Expenses:

 Engineering and          38,266       38,451       52,969        123,915       164,272
 Development

 Selling and              46,314       47,257       58,614        148,944       189,298
 Administrative

 Acquired Intangible      8,214        8,214        5,034         24,667        13,671
 Asset Amortization

 In-process Research      -            -            -             -             1,100
 and Development

 Restructuring and        5,189        15,270       28,589        36,424        53,100
 Other, net (2)

  Operating Expenses      97,983       109,192      145,206       333,950       421,441

Income/(Loss) from        8,772        (62,063 )    (17,276 )     (146,706 )    (1,160  )
Operations

 Interest & Other (3)     (3,597  )    (6,905  )    (3,111  )     (15,555  )    4,419

Income/(Loss) from
Continuing Operations     5,175        (68,968 )    (20,387 )     (162,261 )    3,259
Before Income Taxes

 Income Tax               (1,500  )    (2,200  )    3,070         (11,500  )    13,270
 (Benefit)/Provision

Income/(Loss) from        6,675        (66,768 )    (23,457 )     (150,761 )    (10,011 )
Continuing Operations

Income from
Discontinued              -            -            768           -             768
Operations Before
Income Taxes

 Income Tax               -            -            -             -             -
 (Benefit)/Provision

Income from
Discontinued              -            -            768           -             768
Operations

Net Income/(Loss)       $ 6,675      $ (66,768 )  $ (22,689 )   $ (150,761 )  $ (9,243  )

Income/(Loss) per
Common Share from
Continuing Operations:

Basic                   $ 0.04       $ (0.39   )  $ (0.14   )   $ (0.87    )  $ (0.06   )

Diluted                 $ 0.04       $ (0.39   )  $ (0.14   )   $ (0.87    )  $ (0.06   )

Net Income/(Loss) per
Common Share:

Basic                   $ 0.04       $ (0.39   )  $ (0.13   )   $ (0.87    )  $ (0.05   )

Diluted                 $ 0.04       $ (0.39   )  $ (0.13   )   $ (0.87    )  $ (0.05   )

Weighted Average          174,495      173,022      168,769       173,216       171,058
Common Shares - Basic

Weighted Average
Common Shares -           180,792      173,022      168,769       173,216       171,058
Diluted

Net Orders              $ 288,048    $ 227,331    $ 198,072     $ 651,725     $ 827,067

(1) Cost of Revenues    Quarter Ended:                          Nine Months Ended:
includes:

                        October 4,   July 5,      September     October 4,    September
                        2009         2009         28, 2008      2009          28, 2008

  Provision for Excess
  and Obsolete          $ 6,915      $ 11,491     $ 21,715      $ 27,003      $ 24,969
  Inventory

  Cost for Purchase
  Accounting Inventory    5,700        3,924        -             10,863        4,346
  Step-up

  Sale of Previously
  Written Down            (588    )    -            (528    )     (588     )    (1,442  )
  Inventory

  Insurance Recovery      -            (1,000  )    -             (1,000   )    -
  Gain

                        $ 12,027     $ 14,415     $ 21,187      $ 36,278      $ 27,873

(2) Restructuring and
other, net consists     Quarter Ended:                          Nine Months Ended:
of:

                        October 4,   July 5,      September     October 4,    September
                        2009         2009         28, 2008      2009          28, 2008

  Facility Related      $ 4,419      $ -          $ 3,404       $ 4,419       $ 16,424

  Employee Severance      1,237        14,976       2,620         32,891        15,243

  Eagle Test Purchase
  Accounting              (467    )    (774    )    -             (1,954   )    -
  Adjustment & Other

  Long-Lived Asset        -            1,068        -             1,068         550
  Impairment

  Loss on Sale of Real    -            -            22,565        -             20,883
  Estate

                        $ 5,189      $ 15,270     $ 28,589      $ 36,424      $ 53,100

(3) Interest and Other  Quarter Ended:                          Nine Months Ended:
includes:

                        October 4,   July 5,      September     October 4,    September
                        2009         2009         28, 2008      2009          28, 2008

  Amortization of GAAP
  Imputed Convertible   $ 2,329      $ 2,251      $ -           $ 4,580       $ -
  Debt Discount

  Expense for Deferred
  Debt Financing Costs
  as a Result of

  Repayment and
  Termination of the      -            2,488        -             2,488         -
  Revolving Line of
  Credit

  Other-Than-Temporary
  Impairment and
  Realized

  (Gains)/Losses on
  Marketable              (572    )    -            8,437         2,000         8,437
  Securities

  Gain on Sale of an      -            -            (2,811  )     -             (2,811  )
  Equity Investment

  Gain on Life            -            -            (1,352  )     -             (1,352  )
  Insurance

  Charge for
  Acquisition             -            -            1,227         -             1,227
  Financing Fees

                        $ 1,757      $ 4,739      $ 5,501       $ 9,068       $ 5,501




CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

                                         October 4, 2009  December 31, 2008

Assets

 Cash and Cash Equivalents               $ 406,741        $ 322,705

 Marketable Securities                     5,735            -

 Accounts Receivable                       139,693          109,625

 Inventories (1)                           111,970          168,451

 Deferred Tax Assets                       17,561           16,988

 Prepayments and Other Current Assets      60,348           60,884

                                           742,048          678,653

 Net Property, Plant and Equipment         250,151          298,449

 Long-Term Marketable Securities           55,033           51,613

 Intangible Assets                         160,592          186,998

 Other Assets                              18,669           19,534

                                         $ 1,226,493      $ 1,235,247

Liabilities

 Accounts Payable                          70,613           61,164

 Current Debt (2)                          2,237            122,500

 Accrued Employees' Compensation and       52,053           73,521
 Withholdings

 Deferred Revenue and Customer Advances    127,993          58,030

 Other Accrued Liabilities                 50,184           51,748

                                           303,080          366,963

 Retirement Plans Liabilities              134,465          125,877

 Deferred Tax Liabilities                  3,045            8,730

 Other Long-Term Liabilities               23,623           27,565

 Long-Term Debt (2) (3)                    138,970          -

                                           603,183          529,135

Shareholders' Equity                       623,310          706,112

                                         $ 1,226,493      $ 1,235,247

(1) As of October 4, 2009 and December 31, 2008, Inventories included
approximately $4.5 million and $15.4 million, respectively, for Eagle Test
inventory fair value step-up.

(2) On March 31, 2009, we entered into a loan agreement in Japan for
approximately $10 million. The loan has a term of 5 years and a fixed
interest rate of 1.4%. At October 4, 2009, $2.2 million of the outstanding
loan principal is included in current debt and $7.8 million is classified
as long-term debt.

(3) On March 31, 2009, in connection with our convertible note offering, we
entered into convertible note hedge and warrant transactions. These
transactions are expected to reduce the potential dilution to Teradyne's
common stock upon maturity of the convertible notes. On April 6, 2009, the
convertible note and convertible note hedge and warrant transactions closed
and we netted approximately $163 million of cash, before paying off the
$122.5 million bank revolver.

For information on possible dilution related to the convertible note,
investors should access Teradyne's website at www.teradyne.com and click on
"Investors" and then select the "Financial Data" link.




GAAP to Non-GAAP Earnings Reconciliation

References by the Company to non-GAAP income/(loss) and non-GAAP income/(loss) per share refer to income/(loss)
from continuing operations or income/(loss) per common share from continuing operations excluding goodwill
impairment, in-process research and development, amortization of the GAAP imputed convertible debt discount,
write-off of credit line debt issue costs, restructuring and other, net, certain inventory provision reversals,
fair value inventory step-up related to Nextest and Eagle Test, (losses)/gains on marketable securities and
acquired intangible asset amortization, as well as applicable adjustments to profit sharing and income taxes due
to these exclusions. GAAP requires that these items be included in determining income/(loss) from continuing
operations. Non-GAAP income/(loss) from continuing operations (which is the basis for non-GAAP income/(loss) from
continuing operations per share) gives an indication of Teradyne's baseline performance before gains, losses or
other charges that may not be indicative of our current core business or future outlook.

The Company believes these non-GAAP measures will aid investors' overall understanding of the Company's results
by providing a higher degree of transparency for certain expenses and providing a level of disclosure that will
help investors understand how the Company plans and measures its own business. However, the presentation of
non-GAAP measures is not meant to be considered in isolation or as a substitute for, or superior to, financial
information provided in accordance with GAAP.

(In millions, except per share amounts)

                Quarter Ended:                                             Nine Months Ended:

                October            July 5,             September           October 4,           September
                4, 2009            2009                28, 2008            2009                 28, 2008

Net Revenues    $ 262.2            $ 169.6             $ 297.3             $ 552.4              $ 912.3

Gross Margin -  $ 106.8    40.7 %  $ 47.1     27.8  %  $ 127.9    43.0 %   $ 187.2     33.9  %  $ 420.3    46.1 %
GAAP

 Inventory
 step-up          5.7                3.9                 -                   10.9                 4.3
 reversal (1)

 Insurance        -                  (1.0  )             -                   (1.0   )             -
 recovery

 Inventory
 provision        (0.6  )            -                   (0.5  )             (0.6   )             (1.4  )
 reversal (2)

 Profit
 sharing          (0.4  )            -                   -                   (0.4   )             (0.3  )
 adjustment
 (3)

Gross Margin -  $ 111.5    42.5 %  $ 50.0     29.5  %  $ 127.4    42.9 %   $ 196.1     35.5  %  $ 422.9    46.4 %
non-GAAP

Income/(Loss)
from            $ 8.8      3.4  %  $ (62.1 )  -36.6 %  $ (17.3 )  -5.8 %   $ (146.7 )  -26.6 %  $ (1.2  )  -0.1 %
Operations -
GAAP

 Acquired
 intangible       8.2                8.2                 5.0                 24.7                 13.7
 asset
 amortization

 Inventory
 step-up          5.7                3.9                 -                   10.9                 4.3
 reversal (1)

 Restructuring
 and other,       5.2                15.3                28.6                36.4                 53.1
 net (4)

 Inventory
 provision        (0.6  )            -                   (0.5  )             (0.6   )             (1.4  )
 reversal (2)

 In-process
 research and     -                  -                   -                   -                    1.1
 development

 Insurance        -                  (1.0  )             -                   (1.0   )             -
 recovery

 Profit
 sharing          (2.2  )            -                   -                   (2.2   )             (1.5  )
 adjustment
 (3)

Income/(Loss)
from            $ 25.1     9.6  %  $ (35.7 )  -21.0 %  $ 15.8     5.3  %   $ (78.5  )  -14.2 %  $ 68.1     7.5  %
Operations -
non-GAAP

Income/(Loss)
from
Continuing      $ 6.7      2.6  %  $ (66.8 )  -39.4 %  $ (23.5 )  -7.9 %   $ (150.8 )  -27.3 %  $ (10.0 )  -1.1 %
Operations -
GAAP

 Acquired
 intangible       8.2                8.2                 5.0                 24.7                 13.7
 asset
 amortization

 Inventory
 step-up          5.7                3.9                 -                   10.9                 4.3
 reversal (1)

 Restructuring
 and other,       5.2                15.3                28.6                36.4                 53.1
 net (4)

 Interest and     1.8                4.7                 5.5                 9.1                  5.5
 other (5)

 Inventory
 provision        (0.6  )            -                   (0.5  )             (0.6   )             (1.4  )
 reversal (2)

 In-process
 research and     -                  -                   -                   -                    1.1
 development

 Insurance        -                  (1.0  )             -                   (1.0   )             -
 recovery

 Profit
 sharing          (2.2  )            -                   -                   (2.2   )             (1.5  )
 adjustment
 (3)

 Income tax
 adjustment       -                  -                   -                   (2.9   )             0.2
 (6)

Income/(Loss)
from
Continuing      $ 24.8     9.5  %  $ (35.7 )  -21.0 %  $ 15.1     5.1  %   $ (76.4  )  -13.8 %  $ 65.0     7.1  %
Operations -
non-GAAP

GAAP Income/
(Loss) per
Common Share
from            $ 0.04             $ (0.39 )           $ (0.14 )           $ (0.87  )           $ (0.06 )
Continuing
Operations -
Basic

Non-GAAP
Income/(Loss)
per Common
Share from      $ 0.14             $ (0.21 )           $ 0.09              $ (0.44  )           $ 0.38
Continuing
Operations -
Basic

GAAP and
Non-GAAP
Weighted          174.5              173.0               168.8               173.2                171.1
Average Common
Shares - Basic

GAAP Income/
(Loss) per
Common Share
from            $ 0.04             $ (0.39 )           $ (0.14 )           $ (0.87  )           $ (0.06 )
Continuing
Operations -
Diluted

Non-GAAP
Income/(Loss)
per Common
Share from      $ 0.14             $ (0.21 )           $ 0.09              $ (0.44  )           $ 0.37
Continuing
Operations -
Diluted

GAAP Weighted
Average Common    180.8              173.0               168.8               173.2                171.1
Shares -
Diluted

Non-GAAP
Weighted
Average Common    179.0              173.0               170.3               173.2                173.4
Shares -
Diluted

(1) Reversal of Nextest and Eagle Test purchase accounting inventory step-up.

(2) Reversal of previously written down inventory for non-FLEX products in the Semiconductor Test Division.

(3) Profit sharing adjustment for non-GAAP items.

(4) Restructuring and other, net consists of (in millions):

                Quarter Ended:                                             Nine Months Ended:

                October            July 5,             September           October 4,           September
                4, 2009            2009                28, 2008            2009                 28, 2008

  Facility      $ 4.4              $ -                 $ 3.4               $ 4.4                $ 16.4
  Related

  Employee        1.2                15.0                2.6                 32.9                 15.2
  Severance

  Eagle Test
  Purchase
  Accounting      (0.4  )            (0.8  )             -                   (2.0   )             -
  Adjustment &
  Other

  Long-Lived
  Asset           -                  1.1                 -                   1.1                  0.6
  Impairment

  Loss on Sale
  of Real         -                  -                   22.6                -                    20.9
  Estate

                $ 5.2              $ 15.3              $ 28.6              $ 36.4               $ 53.1

(5) For the quarter and nine months ended October 4, 2009, Interest and Other included amortization of the GAAP
imputed convertible debt discount. For the quarter ended July 5, 2009 and nine months ended October 4, 2009,
Interest and Other included a charge to expense deferred debt financing costs as a result of the repayment and
termination of Teradyne's revolving line of credit. For the nine months ended October 4, 2009, Interest and Other
included a charge for other-than-temporary impairment and realized (losses)/gains on marketable securities.

(6) Income tax adjustment for non-GAAP items. For the nine months ended October 4, 2009, the income tax
adjustment related to a discrete foreign exchange item.

For press releases and other information of interest to investors, please visit Teradyne's homepage on the World
Wide Web at http://www.teradyne.com.




    Source: Teradyne, Inc.


Related Categories

Press Releases

Stocks Mentioned

TER 8.78

+0.02 +0.23%
Volume: 157,181
Track TER


Add Your Comment